Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial. | Arnold et al. Arthritis Research Therapy 2011 13 R86 http arthritis-research.eom content 13 3 R86 RESEARCH ARTICLE Open Access Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine secondary analysis of a randomized placebo-controlled trial Lesley M Arnold1 Fujun Wang2 Jonna Ahl3 Paula J Gaynor4 and Madelaine M Wohlreich4 Abstract Introduction Fatigue is one of the most disabling symptoms associated with fibromyalgia that greatly impacts quality of life. Fatigue was assessed as a secondary objective in a 2-phase 24-week study in outpatients with American College of Rheumatology-defined fibromyalgia. Methods Patients were randomized to duloxetine 60-120 mg d N 263 or placebo N 267 for the 12-week acute phase. At Week 12 all placebo-treated patients were switched to double-blind treatment with duloxetine for the extension phase. Fatigue was assessed at baseline and every 4 weeks with the Multidimensional Fatigue Inventory MFI scales General Fatigue Physical Fatigue Mental Fatigue Reduced Activity and Reduced Motivation. Other assessments that may be associated with fatigue included Brief Pain Inventory BPI average pain numerical scales to rate anxiety depressed mood bothered by sleep difficulties and musculoskeletal stiffness. Treatment-emergent fatigue-related events were also assessed. Changes from baseline to Week 12 and from Week 12 to Week 24 were analyzed by mixed-effects model repeated measures analysis. Results At Week 12 duloxetine versus placebo significantly all p .05 reduced ratings on each MFI scale BPI pain anxiety depressed mood and stiffness. Improvement in ratings of being bothered by sleep difficulties was significant only at Weeks 4 and 8. At Week 24 mean changes in all measures indicated improvement was maintained for patients who received duloxetine for all 24 weeks n 176 . Placebo-treated patients switched to duloxetine n 187 had significant within-group improvement in Physical Fatigue Weeks 16 20 .